Clinical Trial Detail

NCT ID NCT02451930
Title A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

Necitumumab

Pembrolizumab

Age Groups: adult

No variant requirements are available.